Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does ADALIMUMAB Cause Peripheral arterial occlusive disease? 116 Reports in FDA Database

Grow Your Own Natural Pharmacy at Home

Medicinal Garden Kit — 10 healing herbs, 4,818 seeds + step-by-step guide.

Get the Kit

According to the FDA Adverse Event Reporting System (FAERS), 116 reports of Peripheral arterial occlusive disease have been filed in association with ADALIMUMAB (YUSIMRY). This represents 0.0% of all adverse event reports for ADALIMUMAB.

116
Reports of Peripheral arterial occlusive disease with ADALIMUMAB
0.0%
of all ADALIMUMAB reports
5
Deaths
72
Hospitalizations

How Dangerous Is Peripheral arterial occlusive disease From ADALIMUMAB?

Of the 116 reports, 5 (4.3%) resulted in death, 72 (62.1%) required hospitalization, and 3 (2.6%) were considered life-threatening.

Is Peripheral arterial occlusive disease Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for ADALIMUMAB. However, 116 reports have been filed with the FAERS database.

What Other Side Effects Does ADALIMUMAB Cause?

Drug ineffective (71,926) Pain (37,514) Arthralgia (35,592) Rheumatoid arthritis (29,817) Fatigue (29,420) Injection site pain (28,679) Headache (19,891) Nausea (19,299) Rash (18,690) Pain in extremity (18,319)

What Other Drugs Cause Peripheral arterial occlusive disease?

NILOTINIB (319) METHOTREXATE (120) RIVAROXABAN (101) PONATINIB (90) IMATINIB (86) ASPIRIN (77) ATORVASTATIN (70) METOPROLOL (70) CALCIUM\DEXTROSE\MAGNESIUM\SODIUM\SODIUM (63) ETELCALCETIDE (63)

Which ADALIMUMAB Alternatives Have Lower Peripheral arterial occlusive disease Risk?

ADALIMUMAB vs ADALIMUMAB-AACF ADALIMUMAB vs ADALIMUMAB-AATY ADALIMUMAB vs ADALIMUMAB-ADAZ ADALIMUMAB vs ADALIMUMAB-ADBM ADALIMUMAB vs ADALIMUMAB-AFZB

Related Pages

ADALIMUMAB Full Profile All Peripheral arterial occlusive disease Reports All Drugs Causing Peripheral arterial occlusive disease ADALIMUMAB Demographics